Drug Details
| General Information of the Drug (ID: DR4180) | ||||
|---|---|---|---|---|
| Name |
Nimustine hydrochloride
|
|||
| Synonyms |
Nimustine HCl; ACNU; Nidran hydrochloride; Nimustine (hydrochloride); Nimustina clorhidrato; CS 439 HCl; UNII-DFR965WKBU; NSC-245,382; DFR965WKBU; Nimustine hydrochloride [JAN]; CHEBI:7576; 52208-23-8; Nidran; MFCD01676942; 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-1-(2-chloroethyl)-1-nitrosourea hydrochloride; 3-((4-Amino-2-methylpyrimidin-5-yl)methyl)-1-(2-chloroethyl)-1-nitrosourea hydrochloride; 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride; 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride; Urea, N'-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(2-chloroethyl)-N-nitroso-, monohydrochloride (9CI); Nimustine hydrochloride (JAN); 1-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-3-(2-chloroethyl)-3-nitrosourea Hydrochloride; Nimustina clorhidrato [Spanish]; CS-439; 3-[(4-azanyl-2-methyl-pyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitroso-urea hydrochloride; Nidran (TN); Nimustine HCl(ACNU); nimustine monohydrochloride; 1-(2-Cloroetil)-1-nitroso-3-((2-metil-4-aminopirimidin-5-il)metil)urea clorhidrato [Spanish]; 1-(4-Amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride; 1-(4-Amino-2-methylpyrimidine-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride; N'-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(2-chloroethyl)-N-nitrosourea HCl; N'-((4-Amino-2-metil-5-pirimidinil)metil)-N-(2-cloroetil)-N-nitrosourea clorhidrato [Spanish]; SCHEMBL98303; C9H14Cl2N6O2; MLS002153238; Nimustine hydrochloride, solid; CHEMBL1256616; DTXSID80204185; AMY23419; BCP11668; ANW-42405; HY-13703A; NSC245382; s5293; AKOS015895226; CCG-267570; MCULE-2422791904; NSC-245382; 1-(2-Cloroetil)-1-nitroso-3-((2-metil-4-aminopirimidin-5-il)metil)urea clorhidrato; 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitrosourea;hydrochloride; N'-((4-Amino-2-metil-5-pirimidinil)metil)-N-(2-cloroetil)-N-nitrosourea clorhidrato; AC-15840; AK683740; SMR001230702; Urea, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-1-(2-chloroethyl)-1-nitroso-, monohydrochloride; WLN: T6N CNJ B1 DZ E1MVNNO&2G; CS-0007733; FT-0630684; N0821; C11276; D01059; 208N238; A825909; A828980; A830740; Q27107532; Nimustine HCl; NSC-245,382; NSC245,382; NSC 245,382; 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-(2-chloroethyl)-3-nitrosourea; 1-[(4-amino-2-methylpyrimidin-5-yl)methyl]-3-(2-chloroethyl)-3-nitrosourea hydrochloride; N'-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitrosourea hydrochloride; Urea, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitroso-
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Brain cancer [ICD-11: 2A00] | Phase 2 | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C9H14Cl2N6O2
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC1=NC=C(C(=N1)N)CNC(=O)N(CCCl)N=O.Cl
|
|||
| InChI |
1S/C9H13ClN6O2.ClH/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10;/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14);1H
|
|||
| InChIKey |
KPMKNHGAPDCYLP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 55661-38-6
|
|||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | PIK3CB | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| Up-regulation | Ratio of Bax to Bcl-2 | |||||
| Down-regulation | NF-KappaB translocation | |||||
| In-vitro Model | U-118MG | CVCL_0633 | Glioma | Homo sapiens | ||
| U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | |||
| U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | |||
| Experimental
Result(s) |
Curcumin potentiates the potent antitumor activity of ACNU against glioblastoma by suppressing the PI3K/AKT and NF-kappaB/COX-2 signaling pathways. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Prostaglandin G/H synthase 1 (COX-1) | Molecule Info | [3] | |
| Prostaglandin G/H synthase 2 (COX-2) | Molecule Info | [3] | ||
| BioCyc | Aspirin-triggered lipoxin biosynthesis | Click to Show/Hide | ||
| 2 | Aspirin triggered resolvin D biosynthesis | |||
| 3 | C20 prostanoid biosynthesis | |||
| 4 | Aspirin triggered resolvin E biosynthesis | |||
| KEGG Pathway | Arachidonic acid metabolism | Click to Show/Hide | ||
| 2 | Metabolic pathways | |||
| 3 | NF-kappa B signaling pathway | |||
| 4 | VEGF signaling pathway | |||
| 5 | TNF signaling pathway | |||
| 6 | Retrograde endocannabinoid signaling | |||
| 7 | Serotonergic synapse | |||
| 8 | Ovarian steroidogenesis | |||
| 9 | Oxytocin signaling pathway | |||
| 10 | Regulation of lipolysis in adipocytes | |||
| 11 | Leishmaniasis | |||
| 12 | Pathways in cancer | |||
| 13 | Chemical carcinogenesis | |||
| 14 | MicroRNAs in cancer | |||
| 15 | Small cell lung cancer | |||
| 16 | Platelet activation | |||
| NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
| 2 | TSH Signaling Pathway | |||
| 3 | IL4 Signaling Pathway | |||
| 4 | TGF_beta_Receptor Signaling Pathway | |||
| 5 | IL5 Signaling Pathway | |||
| Panther Pathway | Endothelin signaling pathway | Click to Show/Hide | ||
| 2 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 3 | Toll receptor signaling pathway | |||
| 4 | CCKR signaling map ST | |||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | Click to Show/Hide | ||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | Click to Show/Hide | ||
| 2 | S1P1 pathway | |||
| 3 | C-MYB transcription factor network | |||
| 4 | Signaling mediated by p38-alpha and p38-beta | |||
| 5 | Calcium signaling in the CD4+ TCR pathway | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | Click to Show/Hide | ||
| 2 | Arachidonic acid metabolism | |||
| 3 | Aryl Hydrocarbon Receptor | |||
| 4 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 5 | Spinal Cord Injury | |||
| 6 | Integrated Pancreatic Cancer Pathway | |||
| 7 | Eicosanoid Synthesis | |||
| 8 | Selenium Micronutrient Network | |||
| 9 | Phase 1 - Functionalization of compounds | |||
